BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Fact checked by" Russ Conroy
News
Article
Conference|Society of Nuclear Medicine & Molecular Imaging Annual Meeting (SNMMI)

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Among 7 patients who were dosed with BMS-986279, 5 showed a strong PET uptake, with 1 patient showing moderate PET uptake, and an additional patient showing no PET uptake.

Among 7 patients who were dosed with BMS-986279, 5 showed a strong PET uptake, with 1 patient showing moderate PET uptake, and an additional patient showing no PET uptake.

BMS-986279, a zirconium-89–labelled anti-Fucosyl-monosialoganglioside-1 (fuc-GM1) monoclonal antibody, showed feasibility as a non-invasive imaging biomarker of whole-body fuc-GM1 expression in a small cohort of patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to results from the first-in-human CA001-050 study (NCT04702880) presented at the 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.1

Findings from the study revealed that BMS-986279 uptake was observed in primary tumors and distant metastases. Among 7 patients who were dosed with BMS-986279, 5 showed a strong PET uptake, with 1 patient showing moderate PET uptake, and an additional patient showing no PET uptake. Furthermore, 4 patients experienced partial responses per RECIST v 1.1 criteria, all of whom exhibited strong tracer uptake and tumor penetration.

Furthermore, 2 patients were progression-free as of data cut-off, and 3 patients had survived, all of whom exhibited strong PET uptake. Of note, 1 patient with strong PET uptake experienced a 3-month progression-free survival (PFS) and was alive as of data cutoff. Another with strong PET uptake progressed after 4.7 months and died after 9.4 months.

The patient with moderate PET uptake experienced a 1.3-month PFS and a 2.9-month overall survival (OS), and the patient who did not experience any PET uptake had a PFS and OS of 1.0 month. In the patient with moderate uptake, large cell neuroendocrine carcinoma was identified, which initially showed stable disease and then early progression not corresponding with fuc-GM1 expression measured by immunohistochemistry (IHC) straining and liquid chromatography-mass spectrometry (LC-MS). In the patient with absent PET uptake, a small brain lesion showed no clear uptake.

“The [BMS-986279] tracer is suitable for human dosing and proves capable of non-invasive assessment of whole-body fuc-GM1 in the [ES-SCLC] population,” Diederik Grootendorst, MSc, PhD, global scientific director of Clinical Oncology Imaging at Bristol Myers Squibb, stated in the presentation.1 “PET positivity corresponded with fuc-GM1 expression per IHC and LC-MS, although the sample size was limited. Results suggest that tumor penetration of the atigotatug monoclonal [antibody] labeled with zirconium-89 in positive lesions is strong in lung, liver, and bone lesions.”

A total of 15 of 120 patients with treatment-naïve ES-SCLC with an ECOG performance status of 0 to 1 in the CA001-050 study were assigned to receive chemotherapy, nivolumab (Opdivo), atigotatug, and BMS-986279 in a PET substudy. The remaining 105 were randomly assigned 1:1 to receive either chemotherapy, nivolumab, and atigotatug or chemotherapy and nivolumab. Those enrolled were stratified by liver metastases and performance status.

Patients in the substudy received carboplatin, etoposide, and nivolumab with or without atigotatug and BMS-986279 as induction therapy for four 21-day cycles and received treatment every 3 weeks. Subsequent maintenance therapy with nivolumab with or without atigotatug occurred in 28-day cycles until disease progression, unacceptable toxicity, or 2 years of follow-up.

The first 5 patients of the substudy were given 37 MBq of intravenous BMS-986279 and underwent whole body PET on days 1, 4 ± 1, 6 ± 1, and 8 ± 1 to determine its safety, biodistribution, and dosimetry. Thereafter, patients received 37 MBq of BMS-986279 and underwent whole body PET on day 8 ± 1. The investigational tracer was found suitable for human dosing with no tracer-related adverse effects.

The primary end point of the trial was PFS by blinded independent committee review per RECIST v 1.1 criteria. Secondary end points included objective response rate, duration of response, OS, and immunogenicity.2 The exploratory end point of the PET substudy was associations of BMS-986279 PET tracer uptake of biopsied lesions with fuc-GM1 expression levels by IHC, LC-MS, and clinical outcomes.

References

  1. Grootendorst DJ, Hiltermann JN, Bahce I, et al. First in human medical imaging of zirconium-89 labelled anti-fuc-GM1 monoclonal antibody (BMS-986279) in patients with extensive-stage small cell lung cancer. Presented at 2025 Society of Nuclear Medicine & Molecular Imaging Annual Meeting; June 21-24, 2025; New Orleans, LA. SS19
  2. A study of BMS-986012 in combination with carboplatin, etoposide, and nivolumab as first-line therapy in extensive-stage small cell lung cancer. ClinicalTrials.gov. Updated July 17, 2024. Accessed June 25, 2025. https://tinyurl.com/t366z5ah
Recent Videos
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Related Content
Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Considerations for CAR T Use Across Large B-Cell Lymphoma Variants

Roman Fabbricatore
August 8th 2025
Article

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 1st 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.